- Details
- Veda Giri discusses her roles as director of the Cancer Genetics and Prevention Program and the Early-Onset Cancer Program at Yale Cancer Center, highlighting her path through medical school, where her interest in genetics and patient care deepened. Her career was significantly shaped by mentors and opportunities that arose during her residency and fellowships, emphasizing the importance of mentor...
|
- Details
- Alexandra Sokolova discusses her team's study on genomic alterations influencing the response to lutetium-177 PSMA in metastatic castration-resistant prostate cancer. Their research highlights the need for better biomarkers to predict patient outcomes with lutetium-177 PSMA, as not all patients respond to this treatment. Utilizing data from a collaborative database of over 2000 patients, Dr. Sokol...
|
- Details
- Andrea Miyahira speaks with Ulka Vaishampayan who shares insights into her leadership roles, including chairing the phase I team, co-leading the Translational Clinical Research Program, and serving as chief of Ambulatory Clinical Services. Her journey from lymphoma research to GU oncology was sparked by an early passion for clinical trials and a drive to address gaps in prostate, bladder, and kidn...
|
- Details
- Tanya Dorff discusses her team's Phase 1 trial on PSCA CAR T cell therapy for metastatic castration-resistant prostate cancer, published in Nature Medicine. Dr. Dorff highlights that prostate cancer's immunosuppressive environment poses significant challenges, making the development of potent therapies like CAR T cells crucial. The trial involved administering CAR T cells, initially without and th...
|
- Details
- Alicia Morgans speaks with Zach Klaassen about his research focusing on the intersection of mental health and prostate cancer care in the veterans’ population. Dr. Klaassen shares insights from his extensive study aimed at creating the world's largest prostate cancer mental health database. Initial findings reveal that veterans with mental health issues are less frequently diagnosed with prostate...
|
- Details
- Andrea Miyahira talks with Hiba Khan about her presentation on germline genetic associations in prostate cancer. Dr. Khan's study, leveraging data from Invitae, explores genetic testing results linked to medical records to identify gene-specific associations and potential disparities in testing among diverse populations. Key findings reveal that BRCA2 is the most common mutation across all demogra...
|
- Details
- Michael Schweizer discusses findings on Mevrometostat, an EZH2 inhibitor, combined with enzalutamide in treating metastatic castration-resistant prostate cancer (mCRPC). Dr. Schweizer highlights that EZH2 is a significant driver in neuroendocrine prostate cancer (NEPC) development, making it a crucial target for treatment. The Phase I/II trial shows that Mevrometostat combined with enzalutamide yi...
|
- Details
- Edmond Kwan discusses his latest research on circulating tumor DNA (ctDNA) as a predictive marker for response to Lutetium PSMA-617 versus cabazitaxel. The Phase II TheraP trial compared these treatments in patients with advanced metastatic castration-resistant prostate cancer, utilizing dual imaging selection. Dr. Kwan highlights that ctDNA fraction, the proportion of tumor-derived DNA in circula...
|
- Details
- Ping Mu discusses his team's paper, "ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity in AR-Targeted Therapy Resistance in Prostate Cancer," published in Cancer Discovery. Dr. Mu explains that while primary prostate cancer can be managed effectively, resistance to androgen receptor (AR)-targeted therapies in metastatic cases remains a significant challenge. His research identifies the zin...
|
- Details
- Neal Shore interviews Nicholaus Ngowi and Blandina Mmbaga about their work in prostate cancer education and screening in Tanzania. Dr. Ngowi discusses a community-based study revealing that many men in Northern Tanzania have poor knowledge about prostate cancer and face barriers such as misconceptions and cost, leading to late-stage diagnoses. The study, funded by grants from the Prostate Cancer F...
|